Team:Stony Brook/HP/Silver

Stony Brook 2017

Our team also collaborated with iGEM Cornell and iGEM Columbia to analyze the perceptions of people within a large sample population regarding synthetic biology and the willingness to receive treatment or products that are bacteria-regulated or have some component of genetic engineering. We also reached out health professional and pediatric specialist at Stony Brook Hospital, Dr. Sharon Nachman, who gave her insight regarding ways to improve upon our project, so that our bacteriocins and hybrids can be applied as a therapeutic. Her concern was that often times, infected MRSA patients may also have other strains of S. aureus in their body, thus we should consider testing whether our hybrids are only specific to MRSA or other S. aureus strains as well.